🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron UK Patents

Full USPTO pharma patent portfolio for Regeneron UK — grant dates, expiration, and drug cross-links.

Patents
837
Expiring ≤24m
26

Quick answer

Regeneron UK has 837 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 26 expire within 24 months — use filters for patent-cliff planning.

Page 8 of 18

  1. US 11274342

    Systems and methods for sequencing T cell receptors and uses thereof

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11267893

    Anti-IL36R antibodies

    Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11261248

    Restricted immunoglobulin heavy chain mice

    Expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11253572

    Use of a VEGF antagonist to treat angiogenic eye disorders

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11254752

    Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11248044

    Methods for altering body composition by administering a GDF8 inhibitor and an Activin A inhibitor

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11241498

    Room temperature stable lyophilized protein

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11241499

    Human serum albumin in formulations

    Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11214621

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11208458

    Compositions and methods for internalizing enzymes

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11191844

    Multispecific antigen-binding molecules and uses thereof

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11186625

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11178860

    Humanized C5 animals

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11180540

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11174305

    Human antibodies to Fel d1 and methods of use thereof

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11174283

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11167004

    Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11168111

    Readily isolated bispecific antibodies with native immunoglobulin format

    Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11155621

    Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11155598

    GPR156 variants and uses thereof

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11155633

    Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11142578

    Anti-MET antibodies, bispecific antigen binding molecules that bind MET, and methods of use thereof

    Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11130999

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11129903

    Multispecific antigen-binding molecules and uses thereof

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11117955

    Anti-Zika virus antibodies and methods of use

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11117970

    Human antibodies to PD-L1

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11116839

    Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)

    Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11104729

    Anti-IL-33 antibodies and uses thereof

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11104715

    Methods for producing aflibercept in chemically defined media having reduced aflibercept variants

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11102961

    Non-human animals having a humanized lymphocyte-activation gene 3

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11104730

    Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11103552

    High concentration VEGF receptor fusion protein containing formulations

    Expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11098311

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11098127

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11098112

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Aug 19 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11084865

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11072656

    Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11071780

    Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11066458

    VEGF antagonist formulations suitable for intravitreal administration

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11066474

    Anti-TrkB monoclonal antibodies and methods of use

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11064685

    Non-human animal models of retinoschisis

    Expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11059896

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    Expires Mon Jul 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11053309

    Methods for treating active eosinophilic esophagitis

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11051499

    Genetically modified mice and engraftment

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11053280

    Anti-VEGF protein compositions and methods for producing the same

    Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11045522

    Glucagon-like peptide 1 receptor agonists and uses thereof

    Expires Mon Jun 24 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11034768

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11026997

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron UK have?

837 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron UK patents expire?

26 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.